secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000950170-24-025408
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics FY2023 net loss $235.9M; positive DM1/DMD data and $345M offering extend runway to 2025
--------------------------------------------------------------------------------

- Q4 net loss $66.6M ($1.09/shr) vs $38.8M ($0.74/shr) YoY; FY2023 net loss $235.9M ($3.95/shr).
- Cash, equivalents and securities $123.1M at 12/31/23; Jan 2024 $345M public offering (net ~$323.9M) extends runway through 2025.
- Initial ACHIEVE (DM1) data: dose-dependent splicing correction and functional myotonia improvement at 1.8 mg/kg dose.
- Initial DELIVER (DMD exon 51) data: dystrophin expression exceeded eteplirsen with 24-fold lower total PMO dose; favorable safety.
- Plan to report higher-dose cohort data from both trials in H2 2024; goal to initiate registrational cohorts by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/0000950170-24-025408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024025408/dyn-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-025408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer